685 / 1835
StiL R-Benda vs R-CHOP
Rummel MJ et al : Lancet Feb 20, 2013
~ PFS; Primary end-point NOT censored for other therapies ~
•B-R more favorable acute tolerability profile. Severe neutropenia was markedly decreased with B-R (29% vs. 69% with
RCHOP), less parasthesias, stomatitis and infections